
QuickMind MRI
An AI-assisted imaging platform for the assessment of dementia, Alzheimer’s disease and cerebrovascular disease. Supported MRI sequences provide quantitative brain measurements and structured findings for specialist review.
We bring together neuroscience, artificial intelligence, and digital technologies to make brain health assessment and care more accessible.


Connect cognitive assessment and quantitative imaging with clinician-led neurological evaluation.
QuickMind cognitive and motor practice in facilities, with supported home continuation.
Quantitative MRI analysis provides supplementary imaging information for clinician-led assessment of brain disorders.
CT, vascular and perfusion outputs for multidisciplinary stroke assessment.
Applications follow clinician review and local product availability. Photos and imaging show product-use examples.
Dementia, stroke,
autism and ADHD.

An AI-assisted imaging platform for the assessment of dementia, Alzheimer’s disease and cerebrovascular disease. Supported MRI sequences provide quantitative brain measurements and structured findings for specialist review.
An integrated AI-assisted imaging platform for acute stroke assessment, bringing CT, vascular reconstruction and perfusion analysis into one clinical review workflow.

A dedicated VR and eye-tracking system for cognitive screening and rehabilitation in adults and older adults. Structured assessment tasks, personalized cognitive and motor training, and session records support care from the clinic to guided home practice.

A VR-based system combining immersive scenarios, eye-tracking tasks and AI-assisted analysis to support autism assessment and individualized rehabilitation training. Clinicians select activities and interpret task results within the care plan.

A VR-based system combining immersive scenarios, eye-tracking tasks and AI-assisted analysis to support ADHD assessment and individualized rehabilitation training. Clinicians select activities and interpret task results within the care plan.
Single-location study. Screening supports further clinical evaluation.
Software agreement study. Clinical-outcome benefit was not established.
Research-stage estimates. Synthetic PET does not replace confirmatory testing.
Six markets with source documents. Three registration workstreams in progress.

Selected companies and institutions identified by YIWEI. Roles vary by product and project.
We welcome conversations with healthcare providers, research institutions, and international distribution partners.